Medtronic and Johnson & Johnson present cardiac ablation data at APHRS 2026

At the APHRS 2026 meeting, Medtronic presented registry data for its Sphere-9 catheter and PulseSelect PFA System, while Johnson & Johnson presented studies of its VARIPULSE Pro and investigational OMNYPULSE platforms. Medtronic reported a 1.1% major complication rate in 1,050 AFib patients treated with Sphere-9 and a 0.09% acute major complication rate for PulseSelect in 1,160 patients. Johnson & Johnson reported 100% acute procedural success in 225 VARIPULSE Pro patients and 82.5% freedom from documented atrial arrhythmia recurrence at 12 months for 136 OMNYPULSE patients under stringent monitoring.

The findings add real-world and clinical evidence for competing cardiac ablation systems, with potential implications for adoption across electrophysiology practices. Johnson & Johnson said the results strengthen the clinical evidence supporting its pulsed-field ablation portfolio, while VARIPULSE Pro is not approved in the United States.

  • 1The APEX registry included 1,050 AFib patients and reported a 1.1% major complication rate with the Sphere-9 catheter.
  • 2The REAL PULSE registry included 1,160 AFib patients treated with the PulseSelect PFA system.
  • 3VARIPURE evaluated 225 patients across 19 European centers and recorded 100% acute procedural success with one primary adverse event, representing 0.4%.
  • 4Omny-IRE evaluated 136 patients, with 82.5% free from documented atrial fibrillation, atrial flutter or atrial tachycardia recurrence at 12 months under stringent monitoring.
  • 5Medtronic's Sphere-9 catheter achieved an 87% acute success rate in a European ventricular tachycardia ablation analysis.
  • 6Medtronic's PulseSelect system showed a 0.09% major complication rate in 1,160 global patients.

Sources